AstraZeneca's London-listed shares fell 2% in morning trading after a U.S. Food and Drug Administration (FDA) advisory panel voted 6-3 against approving the company's oral cancer drug camizestrant for a type of breast cancer tumor, citing concerns around the trial design [1]. The panel was not convinced that the SERENA-6 Phase 3 trial proved early switching to camizestrant improved long-term survival rates compared to alternative treatments, despite the trial showing a 56% reduction in the risk of disease progression or death versus standard of care [1].
The FDA generally follows the recommendations of its advisory committees, though it is not required to do so [1]. Panel members did not express significant concern about the drug's toxicity or overall safety, but questioned whether acting on tumor detection before radiographic progression leads to better long-term outcomes [1]. Jefferies analysts noted that doctors felt the data did not support an early change in therapy and could introduce unknown risks by accelerating the treatment sequence, potentially reducing time on otherwise effective options [1]. The group described SERENA-6 as advocating too large a shift in clinical practice for what they viewed as a modest and uncertain benefit [1].
Barclays analyst James Gordon commented that while the vote outcome is negative for the near-term regulatory path, the panel did not dismiss the drug's efficacy or future potential [1]. AstraZeneca stated it would continue to work with the FDA as it completes its review of the application for camizestrant, and Executive Vice President of Oncology Haematology R&D Susan Galbraith affirmed the company's strong belief in the drug [1].
Jefferies analysts also pointed out that this result was not part of their Buy thesis on AstraZeneca, and that SERENA-6 represented only a small part of the company's $80 billion 2030 sales goal. They suggested that outside of a potential sentiment hit, this should not be a major issue for the company [1]. AstraZeneca shares have risen about 25% over the past 12 months, outperforming the FTSE 100's 20%, and the company anticipates a catalyst-rich period ahead with 11 more data readouts expected in 2026 [1].
CONCLUSION
The FDA panel's negative vote on camizestrant led to a modest decline in AstraZeneca's share price, but analysts suggest the long-term impact on the company is limited given the drug's small role in overall sales targets. AstraZeneca remains optimistic about its pipeline and future catalysts, and will continue to engage with the FDA regarding camizestrant's approval process.